Måndag 3 November | 11:38:20 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-11 N/A Extra Bolagsstämma 2025
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning ABS 0.00 NOK
2025-05-26 - Årsstämma
2025-05-07 - Bokslutskommuniké 2024
2024-11-19 - Extra Bolagsstämma 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-29 - X-dag ordinarie utdelning ABS 0.00 NOK
2024-04-26 - Årsstämma
2024-04-09 - Bokslutskommuniké 2023
2023-09-29 - Kvartalsrapport 2023-Q2
2023-04-24 - X-dag ordinarie utdelning ABS 0.00 NOK
2023-04-21 - Årsstämma
2023-03-29 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning ABS 0.00 NOK
2022-05-05 - Årsstämma
2022-04-07 - Bokslutskommuniké 2021
2021-11-10 - Extra Bolagsstämma 2021
2021-08-26 - Kvartalsrapport 2021-Q2

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Arctic Bioscience är ett bioteknikföretag som utvecklar och kommersialiserar läkemedelsprodukter och kosttillskott baserade på bioaktiva marina råvaror. Bolaget utvecklar HRO350, en ny läkemedelskandidat för behandling av patienter med mild till måttlig psoriasis. Kosttillskott säljs globalt både som bulkingredienser och som färdiga produkter under varumärket ROMEGA, till både företag och privatkunder.
2025-10-28 09:30:00

An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 11 November 2025 at 10:00 (CET), as a digital meeting.

The agenda of the meeting is election of a new auditor for the Company. The elected auditor, PwC, has informed Arctic Bioscience AS of corporate reorganization that will result in a portion of their business, including partners, employees and clients, being moved to a wholly owned subsidiary. Arctic Bioscience AS is one of the clients that has been moved to the wholly owned subsidiary. The move does not entail any changes to the services provided. The reorganization of PwC therefore only has the practical effect that PwC's subsidiary, PwC Assurance AS, must be elected as auditor instead of PwC AS. See notice for more information.

Shareholders are encouraged to cast their votes in advance of the General Meeting or grant the Chair of the Board a proxy, with or without voting instructions.

Deadline for registration of attendance, advance votes, proxy or instructions is 7 November 2025 at 16:00 (CET). For attendance to the live event, please follow the instructions in the notice.

For further information, see the attached Notice of the Extraordinary General Meeting, which can also be accessed from the company's website (https://arctic-bioscience.com/investors/general-meetings/).

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.